Table 1.
Historical excursus of publications on CD-based NSs employed in pharmaceutical research.
| Year | Nanosponge/Cross-Linker | Drug | Indication | References |
|---|---|---|---|---|
| 2010–2015 | β-CD/DPC | Camptothecin | Pharmaceutical application | [46,70] |
| β-CD/CDI | Resveratrol | Pharmaceutical application | [58] | |
| Fluorescent NS | Paclitaxel | Pharmaceutical application | [45] | |
| Carboxylated nanosponges | Acyclovir | Antivirial efficacy | [51] | |
| β-CD/CDI | Rutin, phloridzin and chlorogenic acid | Anti-cancer, anti-diabetic, antiobesity, neuronal protective properties etc. | [57] | |
| β-CD/DPC | Gabapentin | Treatment of partial seizures in pediatric | [71] | |
| 2016 | β-CD/PMDA | Lansoprazole | Gastric ulcers | [72] |
| β-CD/DPC | Quercetin | Cancer treatment | [73] | |
| β-CD /CDI | Erlotinib hydrochloride (ERL) | Cancer treatment | [74] | |
| GSH–NS (β-CD/PMDA) | Doxorubicin | Anticancer activity | [75] | |
| 2017 | β-CD/EDTA | Ibuprofen | diseases | [76] |
| β-CD/DPC | 2-(3,4-dimethoxyphenyl)-3-phenyl-4H-pyrido [1,2-a] pyrimidin-4-one (DB103) | Cardiovascular diseases, drug-eluting stents (DES) | [77] | |
| β-CD/DPC | Chrysin | Optimal anti-oxidant and anti-tumorous properties | [78] | |
| β-CD/DPC | Nifedipine | Treatment of angina pectoris and hypertension | [79] | |
| β-CD/CDI | Camptothecin (CPT) | Antitumor efficacy, inhibition effect on prostate cancer | [80,81] | |
| β-CD/DPC | Cefadroxil (CFD) | Against variety of Gram-positive and Gram-negative bacteria | [82] | |
| β-CD/DPC | Efavirenz and Rilpivirine HCl | HIV | [83,84] | |
| β-CD/PMDA | Erlotinib glutathione | Cancer | [85] | |
| 2018 | β-CD/DMC | Ellagic acid | Cancer | [86] |
| β-CD/DPC | Mebendazole | Lymphatic worm infestations | [16] | |
| β-CD/TDI | Naproxen | Inflammation | [87] | |
| Electrospun | N,N-diethyl-3-toluamide | Infectious diseases | [88] | |
| β-CD/PMDA | ||||
| β-CD/CDI; PMDA | Rilpivrine | HIV | [89] | |
| β-CD/CDI | Atorvastatin calcium | Dyslipidemia | [90] | |
| β-CD/DPC | Norfloxacin | Urinary tract infections | [91] | |
| β-CD/CDI | Doxorubicin | Cancer | [92] | |
| 2019 | β-CD/NDCA | Sage essential oil | Diabetes | [93] |
| β-CD/DPC; PMDA | Curcumin and Resveratrol | Cancer | [15,94,95] | |
| β-CD / DPC | Ferulic acid and Imatinib Mesylate | Cancer | [17,96] | |
| β-CD/EPI | Curcumin | Cancer | [97,98] | |
| β-CD/CDI | Kynurenic acid and Paliperidone | Neurological disorders and Schizophrenia | [99,100] | |
| β-CD/PMDA | Imiquimod | Topical diseases | [101] |